2022 American Transplant Congress
Outcomes After Conversion to Belatacept in Pediatric Kidney Transplantation
Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France
*Purpose: Belatacept (CTLA-Ig) is a selective co-stimulation blocker that is associated with reduced dnDSA, improved renal function, and prolonged allograft survival in adult transplant recipients…2022 American Transplant Congress
Perioperative IL-6 Blockade Promotes Intra-Graft Regulation and Prevents Costimulation-Blockade Resistant Rejection
*Purpose: Our group has recently shown that CTLA4-Ig monotherapy leads to limited murine heart allograft survival associated with decreased Treg frequencies and early acute T-cell…2022 American Transplant Congress
Predictors of Response to Belatacept Conversion in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
1Virginia Commonwealth University, Richmond, VA, 2University of Alberta, Edmonton AB, AB, Canada
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of kidney transplant (KT) loss. Current therapies have unclear efficacy and side effects. We…2022 American Transplant Congress
T and B Cell Response to 3 Dose Covid Vaccine Series for Kidney Transplant Patients on Belatacept
*Purpose: Data shows COVID vaccine response after 2 doses in patients on Belatacept immunosuppression (IS) is low, with reported rates of seroconversion (as measured by…2022 American Transplant Congress
Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates
MGH Center for Transplantation Sciences, Boston, MA
*Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been…2022 American Transplant Congress
TNX-1500, an Fc-Modified Anti-cd154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival
*Purpose: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to replace current clinical immunosuppression. TNX-1500 (TNX) is a novel humanized anti-CD154…2021 American Transplant Congress
IL-10 Signaling in T Cells Modulates Costimulation-independent Activation and is Essential for Transplant Tolerance Induction
*Purpose: Costimulation blockade (CoB)-based immunotherapy remains a very promising approach for better management of transplant recipients. Understanding the mechanisms that impact the efficacy of CoB…2021 American Transplant Congress
Combined CD11b/CD40 Blockade is Superior to CD40 Blockade Alone in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation
*Purpose: Blockade of the CD40/CD154 pathway is highly effective in preventing rejection in pig-to-nonhuman primate (NHP) xenotransplantation models. Clinical translation of anti-CD154 mAbs, however, has…2021 American Transplant Congress
Establishing a Linear Program for the Development of Costimulation Resistant T-Cells
*Purpose: CD4+CD57+PD1-T-cells are primed effectors capable of mediating belatacept-resistant rejection, however, the developmental program giving rise to these cells has not been elucidated in detail.…2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
1Yale University, New Haven, CT, 2Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 30
- Next Page »